UV Viral Inactivation Systems

Virus Kill
Home | Viral Kill | Process | Technology | Accessing Technology | Services

Viral Inactivation
 
The information in tables below formed part of the early work carried out on the first protype systems. They give a guide, but for more information contact 

 
Mammalian Model Viruses used in initial study
 
 
 
 

Virus
Genome/Size Shape
Model for
Hepatitis A Virus (HAV)
ss RNA: 20-30nm;icosahedral;non enveloped
Hepatitis A Virus
Canine Parvovirus (CPV)
ss DNA; 18-26 nm; icosahedral; non enveloped
B19
Bovine Viral Diarrhoea (BVDV)
ss RNA; 45-55 nm; pleo-spherical; enveloped
Hepatitis C

Pseudorabies Virus (PRV)

ds DNA; 120-200nm; sperical; enveloped

Herpes Viruses

Reduction Factors obtained in 4.5% human albumin spiked with mammalian model viruses using the scale-down UVC system at conditions equivalent to flow rates of approximately 4.2L/min in the Production system

HAV
PRV

Experiment No.
Residence Time
(sec)
Log Reduction
Factor
Experiment No.
Residence Time
(sec)
Log Reduction
Factor
1
17.6
   ≥5.2 ± 0.3
1
17.6
2.9 ± 0.4
1
12.9
   ≥5.2 ± 0.3
1
12.9
2.8 ± 0.4
1
10.7
≥5.2 ± 0.3
1
10.7
2.0 ± 0.5
2
17.6
   ≥5.2 ± 0.3
2
17.6
2.9 ± 0.4
2
12.9
   ≥5.2 ± 0.3
2
12.9
2.7 ± 0.5
2
10.7
  ≥5.2 ± 0.3
2
10.7
2.3 ± 0.4

-

CPV
BVDV

Experiment No.
Residence Time
(secs)
Log Reduction
Factor
Experiment No.
Residence Time
(Secs)
Log Reduction
Factor
1
22
≥7.0 ± 0.4
1
17.6
6.2 ± 0.5
1
16
≥7.0 ± 0.4
1
12.9
5.3 ± 0.5
1
12.4
≥7.0 ± 0.4
1
10.7
4.7 ± 0.5
1
10.7
≥7.0 ± 0.4
-
-
-
2
22
≥7.0 ± 0.4
2
17.6
≥5.3 ± 0.5
2
16
≥7.0 ± 0.4
2
12.9
5.6 ± 0.5

2

12.4

≥7.0 ± 0.4

2

10.7

4.7 ± 0.5

2

10.7

≥7.0 ± 0.4

-

-

-